Tandem Diabetes Care (TNDM) Capital Expenditures Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -1.00% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 10.38% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 24.20% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 35.70% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -9.99% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 16.28% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -4.32% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -6.52% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -47.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.49% |
| Mar 31, 2026 | 111.40% |
| Dec 31, 2025 | 139.20% |
| Sep 30, 2025 | 132.68% |
| Jun 30, 2025 | -124.54% |
| Mar 31, 2025 | -7.75% |
| Dec 31, 2024 | -1,085.84% |
| Sep 30, 2024 | 134.95% |
| Jun 30, 2024 | 4.50% |
| Mar 31, 2024 | -63.59% |
| Dec 31, 2023 | 600.40% |
| Sep 30, 2023 | -4,981.02% |
| Jun 30, 2023 | 996.14% |
| Mar 31, 2023 | 1,416.84% |
| Dec 31, 2022 | -71.93% |
| Sep 30, 2022 | -5,800.00% |
| Jun 30, 2022 | 373.94% |
| Mar 31, 2022 | 3,323.53% |
| Dec 31, 2021 | -78.52% |
| Sep 30, 2021 | -100.02% |